media – Page 42 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Ed Biotech forges a precise medical “compass”

Ed Biotech has always focused on research and innovation, steadily moving forward on the path of precise diagnosis of tumors, allowing precision medical products to better play the role of a “compass” and alleviate patients’ pain. Recently, a reporter from Shanghai Securities News came to the Xiamen headquarters of Ed Biotech to listen to their stories of forging ahead and helping China’s precision medicine industry rise to new heights. Take the difficult yet correct path Xiamen Haicang District, Aide Biological Dust free Production Workshop. We can produce 30 types of Class III diagnostic products here, with a daily production capacity of over 100000 people. These products cover various types of cancer with precision medical conditions, and most of them are domestically approved, some of which are even internationally pioneering. When the reporter met with the company’s general manager Luo Jiemin, this “post-80s” PhD had just returned from the academic annual ...
- Source: drugdu
- 132
- December 19, 2024
InterPharma

Organiser：Jakarta International Expo (JI EXPO) Time：October 21st – 24th, 2025 Address：Jl. Gatot Subroto No.1, RT.1/RW.3, Gelora, Kecamatan Tanah Abang, Kota Jakarta Pusat, Daerah Khusus Ibukota Jakarta 10270, Indonesia Exhibition hall：Balai Sidang Jakarta Convention Center Product range: Active Pharmaceutical Ingredients (APIs), intermediates, natural extracts; excipients, formulations, custom manufacturing; biopharmaceuticals, fine chemicals; laboratory equipment, instruments, laboratory supplies, water treatment; environmental and quality control, technical publications; pharmaceutical products, medicines; pharmaceutical engineering, materials, and packaging; pharmaceutical machinery and equipment. About InterPharma： InterPharma, the Pharmaceutical Exhibition in Jakarta, Indonesia, is the largest and most influential pharmaceutical exhibition in Indonesia. It is one of the significant professional exhibitions for pharmaceuticals, medicines, and packaging careers in the Southeast Asian region. The exhibition covers a wide range of products, including APIs, intermediates, biopharmaceuticals, medical supplies, materials and packaging, pharmaceutical machinery and equipment, etc.
- Source: drugdu
- 167
- December 19, 2024
Two innovative medical devices have been approved for market launch

Recently, the National Medical Products Administration approved the registration applications for two innovative products, the “Proton Therapy System” of Maisheng Medical System Company (hereinafter referred to as Maisheng Medical) and the “Cardiac Pulse Electric Field Ablation Device” of Shanghai Hongtong Industrial Co., Ltd. (hereinafter referred to as Shanghai Hongtong). Maisheng Medical, the first product to be launched in China Maisheng Medical was founded in 2004 and is headquartered in Littleton, Greater Boston, Massachusetts, USA. We specialize in the research, development, production, installation, and service of miniaturized proton therapy equipment for cancer treatment, with branch structures in Europe and Asia. We are a leader in the field of miniaturized proton therapy. The miniaturized proton radiotherapy system developed based on its own core technology has unique advantages such as good clinical efficacy, high integration level, small footprint, and low overall customer ownership cost. At present, Maisheng Medical has advanced proprietary intellectual property ...
- Source: drugdu
- 119
- December 19, 2024
5 innovative medical devices enter special review process

On December 16th, the National Medical Products Administration’s Device Review Center released the results of the special review application for innovative medical devices (No. 11 of 2024), intending to approve 5 innovative medical device projects to enter the special review process. 1. Hot steam ablation system: Shanghai Lixiao Medical Technology Co., Ltd Lixiao Medical was founded in January 2019 by Dr. Cheng Lifei, Global Vice President of Business Development at Medtronic. It is an innovative medical technology platform that focuses on the introduction of advanced medical technologies from overseas, local research and development, and industrialization. It specializes in the research and development of medical devices for the treatment of chronic diseases such as cardiovascular, urinary, and respiratory diseases. As of now, Lixiao Medical has completed two rounds of financing of nearly one billion US dollars, led by well-known investment institutions such as Eli Lilly Asia, Sequoia Capital, and WuXi AppTec. ...
- Source: drugdu
- 116
- December 19, 2024
The two weight loss giants were launched on the same day on Meituan. Has the new battle begun?

The battle between the two weight loss giants has officially entered the deep water period. From clinical PK to production capacity competition, to the future layout competition, Novo Nordisk and Eli Lilly are fighting fiercely. With the advancement of the commercialization of the two giants in China, the new battle has surfaced. On December 9, the oral version of semaglutide was launched on Meituan’s entire network, and at the same time, the reservation service for telpotide was also opened. The first confrontation between the two parties in the Chinese market has once again attracted widespread attention from the market. This indicates that we can no longer use the perspective of traditional medicine to view GLP-1R drugs that are increasingly closely integrated with consumer medicine. That is, traditional channels such as pharmacies are certainly very critical, but online channels are also becoming more and more indispensable. Otherwise, Eli Lilly would not ...
- Source: drugdu
- 144
- December 19, 2024
long-acting AIDS prevention drugs rank first

On December 12, 2024, the top ten scientific breakthroughs of the year in Science magazine arrived as expected. An AIDS drug, Lenacapavir, was named the top scientific breakthrough of the year. The drug only needs to be injected once every 6 months and has achieved remarkable success in preventing HIV infection, which is expected to help end the HIV/AIDS epidemic. The interim analysis data of the key Phase 3 clinical trial released by Gilead Sciences showed that twice-yearly dosing achieved 100% AIDS prevention effect in women. On June 20, 2024, Gilead Sciences announced the interim analysis results of its key Phase 3 clinical trial of Lenacapavir, an AIDS prevention drug, showing that only twice-yearly dosing achieved 100% AIDS prevention effect in women. It is reported that this project is the most comprehensive and diverse AIDS prevention trial project ever conducted. Dr. Merdad Parsey, Gilead’s Chief Medical Officer, said that two ...
- Source: drugdu
- 158
- December 19, 2024
From PROTAC to RIPTAC, it is a challenge and an opportunity

In 2001, Craig Crews, the former founder of Arvinas and Professor of Yale University, first proposed the concept of PROTAC, leading a new revolution in small molecule innovative drugs. In 2023, Professor Crews founded HALDA Therapeutics and unveiled their latest technology platform RIPTAC at the ASCO-GU conference. At the same time, he published the latest article on bioRxiv, describing the results of the RIPTAC proof-of-concept study. In 2024, HALDA Therapeutics announced the completion of a $126 million Series B financing, and emphasized that the funds raised will be used for clinical trials of two candidate drugs in patients with prostate cancer and breast cancer. From PROTAC to RIPTAC, it was originally an innovative theory proposed by the same professor, but it is essentially based on two different directions. The former emphasizes the transition from “placeholder-driven” to “event-driven”, while the latter returns from “event-driven” to “placeholder-driven”. What is the reason? More ...
- Source: drugdu
- 117
- December 19, 2024
Mabwell Biotechnology Plans to Issue H Shares

December 15 Mabwell Biotechnology (688062) announced a preliminary announcement regarding its plan to issue H shares and list on the Hong Kong Stock Exchange. The announcement stated that in order to meet the funding needs for the company’s operational development, achieve sustainable growth, and enhance its level of internationalization, the company intends to issue H shares abroad and list on the main board of the Hong Kong Stock Exchange. The company will choose an appropriate time and issuance window to complete this task within the validity period of the shareholders’ meeting resolution. As of now, the company is actively discussing relevant matters concerning the H share issuance with related intermediary institutions, but specific details have not yet been finalized. The announcement emphasized that the review and approval process for the issuance and listing of H shares involves significant uncertainties, and investors should remain vigilant about this situation. In the first ...
- Source: drugdu
- 154
- December 19, 2024
Siemens Healthineers partners with Paris Public Assistance Hospital (AP-HP)

Recently, the largest university hospital system in Europe, Paris Public Assistance Hospital (AP-HP), reached a comprehensive framework agreement with Siemens Healthineers, marking the first such cooperation between the two parties. It is reported that this collaboration aims to address France’s major healthcare challenges by jointly developing innovative solutions for chronic diseases, neurological and cardiovascular diseases, musculoskeletal disorders, and cancer. 01. Joining hands with the largest university hospital system in Europe The agreement was signed by Nicolas Revel, CEO of Paris Public Aid Hospital, Bernd Montag, CEO of Siemens Healthineers, and Hassan Safer Tebbi, Regional Head of Siemens Healthineers France, Belgium, and Luxembourg. It is understood that this is the first time that Paris Public Aid Hospital has carried out such a large-scale cooperation with an imaging company. This collaboration not only involves clinical research, but also encompasses systematic changes in healthcare service provision, utilizing advanced technology to adapt to the ...
- Source: drugdu
- 126
- December 18, 2024
After investing in healthcare, giants may lay off 15000 employees

According to the well-known anonymous workplace community Teamblind, Microsoft plans to lay off 10000 to 15000 employees in January 2025. Once this news was released, it immediately attracted widespread attention from all sectors of society. If the layoff plan is confirmed, it will not only have a significant impact on Microsoft itself, but also affect the entire technology industry. According to insiders, Microsoft’s compensation plan for this round of layoffs may follow the old practice of the “N+2” model. At present, the specific departments involved in the layoff plan and whether it covers the China region are not yet clear. This has increased speculation from the outside world about Microsoft’s future strategic adjustments. Layoffs are usually related to a company’s business restructuring, cost reduction, or strategic transformation, and Microsoft’s move may indicate significant adjustments in certain business areas. It is worth noting that as a tech giant with years of ...
- Source: drugdu
- 145
- December 18, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.